A STUDY ON DETECTION OF GLYCOPEPTIDE RESISTANCE AMONG CLINICAL ISOLATES OF COAGULASE NEGATIVE STAPHYLOCOCCUS (CoNS) SPECIES IN A TERTIARY CARE CENTRE

S. Meerah1, P. A. T. Jagatheeswary2

1Assistant Professor, Department of Microbiology, Chengalpattu Medical College, Chengalpattu, Tamilnadu.
2Professor, Department of Microbiology, Saveetha Medical College, Thandalam, Chennai, Tamilnadu.

ABSTRACT

BACKGROUND
CoNS have become recognised as important agents of hospital acquired infections. Infections with CoNS occur mainly in patients with indwelling foreign devices, neonates and in immunocompromised patients. Some recent studies have pointed out reduced susceptibility of CoNS to Glycopeptide antibiotics.

In view of the above perspective, the present study was carried out in a tertiary care hospital in Madurai to assess the prevalence of Glycopeptide resistant CoNS species in our region and also to assess the antibiotic of choice for them.

MATERIALS AND METHODS
The present study was a cross-sectional study conducted in Institute of Microbiology, Madurai Medical College, Madurai. The study period was from November 2014 to August 2015. A total of 104 CoNS species were isolated from clinical samples, collected from the patients admitted in various wards of Government Rajaji Hospital, Madurai and processed using conventional microbiological methods.

RESULTS
Among the 104 CoNS species 72 were S. epidermidis, 19 were S. lugdunensis, 11 were S. haemolyticus and 2 were S. saprophyticus. Among them, 28 (26.92%) were Methicillin Resistant CoNS (MRCoNS) and 76 (73.08%) were Methicillin Sensitive CoNS (MSCoNS).

Phenotypic detection of Glycopeptide resistance among Methicillin Resistant Staphylococci by various methods showed one isolate 3.6% (among MRCoNS) to be Vancomycin Intermediate S. epidermidis (VISE) from blood sample. This isolate was susceptible to Gentamicin, Teicoplanin, Linezolid, Rifampicin, Quinupristin/Dalfopristin by reference CLSI methods.

CONCLUSION
Early detection of these strains is crucial to establish an appropriate antimicrobial therapy, thereby reducing the mortality and morbidity associated with these infections and also to prevent hospital acquired infections.

KEYWORDS
Glycopeptide Resistance, Indwelling Foreign Devices, Immunocompromised.

the patients before collecting the specimens. A total of 104 CoNS species were isolated from clinical samples, collected from the patients admitted in various wards of Government Rajaji Hospital, Madurai and processed using conventional microbiological methods.

Speciation of CoNS was done based on Kloos and Schleifer classification and Koneman\(^{(1,2)}\) by studying the colony morphology on nutrient agar, Gram reaction of smear, Haemolysis on blood agar, Mannitol salt agar, Catalase test, Coagulase test, Modified oxidase test, nitrate reduction test, Voges-Proskauer test, Urease test, Oxidative fermentative test, DNase test, Phosphatase test, Ornithine decarboxylase, Sugar fermentation-Glucose, lactose, Mannitol, Mannose, Trehalose, Xylose, Novobiocin and Polymyxin B 300 Susceptibility test. Antimicrobial susceptibility testing was done based on CLSI Guidelines.

Identification of MRCONS: (Antibiogram by Kirby-Bauer Disk Diffusion Method)\(^{(3)}\)

All isolates of CoNS were tested by using 30 micrograms of cefoxitin by Disk Diffusion method for Methicillin sensitivity and interpretation was done as per CLSI Guidelines. ATCC S. aureus 25923 was used as negative control (Cefoxitin 30 microgram Zone size 23 - 29 mm). ATCC S. aureus 43300 as positive control with (Zone size ≥ 21 mm).

Phenotypic Detection of Glycopeptide Resistance among Methicillin Resistant Coagulase Negative Staphylococci (n= 28) was analysed.

Vancomycin Screen Agar (BHIA6µg V)\(^{(3)}\)

All the Methicillin Resistant CoNS isolates were screened for vancomycin resistance by Vancomycin screen agar, that is brain heart infusion (BHI) agar containing 6 µg/mL of Vancomycin and is used for the presumptive identification of vancomycin resistance. Spot inoculation of 10 µL of 0.5 McFarland turbidity standard bacterial suspension along with positive and negative control strains was done onto the agar surface. The plates were incubated for 24 hrs. aerobically at 37°C. Growth of greater than 1 colony indicates presumptive vancomycin resistance. It should be confirmed by determining the minimum inhibitory concentration (MIC) for vancomycin and teicoplanin. This test includes E. faecalis ATCC 29212 as negative control (MIC-Vancomycin ≤ 4 microgram/mL), E. faecalis ATCC 51299 as positive control (MIC-Vancomycin ≥ 8 microgram/mL).

E-Test Method: (The Vancomycin and Teicoplanin Minimum Inhibitory Concentration (MIC) for all the Methicillin Resistant CoNS Isolates were tested by E-Test Method)

Preparation of inoculum and the test procedures were done as per the instruction given by the manufacturer (Hi-Media). Interpretation of results were done according to CLSI 2014 guidelines.

MIC reading was done as per manufacturer’s instructions. Read the MIC where the ellipse intersects the MIC scale on the strip. For bactericidal drugs such as Vancomycin, Teicoplanin always read the MIC at the point of complete inhibition of all growth including hazes, microcolonies and isolated colonies, if necessary use magnifying glass. Always round up the value to the next two-fold dilution before categorisation.

Quality Control Strains

ATCC 29213 S. aureus with Vancomycin MIC ≤ 2 microgram/mL and ATCC 700699 (MU50) VISA strains with Vancomycin MIC 4 - 8 microgram/mL were used.

BROTH MICRODILUTION METHOD (BMD)

(The vancomycin and Teicoplanin MIC for all the Methicillin resistant isolates were tested by BMD method).\(^{(4)}\) The test includes S. aureus ATCC 29213 as negative control and S. aureus ATCC 700699 (MU 50) VISA Strain procured from Hi-Media as positive control. Interpretation was done based on CLSI Guidelines.

RESULTS

<table>
<thead>
<tr>
<th>Specimen</th>
<th>CoNS (n=104)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pus</td>
<td>72</td>
</tr>
<tr>
<td>Blood</td>
<td>22</td>
</tr>
<tr>
<td>Body Fluid</td>
<td>8</td>
</tr>
<tr>
<td>Urine</td>
<td>2</td>
</tr>
</tbody>
</table>

Table 1. Specimen Wise distribution of CoNS Species (n=104)

Among the samples 72 CoNS were isolated from pus, 22 were from blood and 8 were from body fluid and 2 from urine samples.

<table>
<thead>
<tr>
<th>Types</th>
<th>No. of Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR CoNS</td>
<td>28</td>
<td>26.92%</td>
</tr>
<tr>
<td>MS CoNS</td>
<td>76</td>
<td>73.08%</td>
</tr>
<tr>
<td>Total</td>
<td>104</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 2. Distribution of MR CoNS and MS CoNS (n=104)
Among the 104 CoNS species, 72 were S. epidermidis, 19 were S. lugdunensis, 11 were S. haemolyticus, 2 were S. saprophyticus. Among them, 28 (26.92%) were Methicillin Resistant CoNS (MRCoNS) and 76 (73.08%) were Methicillin Sensitive CoNS (MSCoNS).

Among the 28 MRCoNS 19 were S. epidermidis, 6 were S.lugdunensis and 3 were S. haemolyticus species. The sample wise distribution of MRCoNS was analysed, which showed highest percentage of MRCoNS isolated in pus sample (20.19%) followed by blood (4.81%) and fluid (1.92%).

The department wise isolation of Methicillin Resistant CoNS was analysed. It showed 9 were from surgery, 6 were from medicine, 7 from ortho, 4 from OG and 2 from paediatric unit.

**Phenotypic Detection of Glycopeptide Resistance among Methicillin Resistant Coagulase Negative Staphylococci (n= 28) was analysed.**

<table>
<thead>
<tr>
<th>Isolate</th>
<th>No. of Isolate</th>
<th>Vancomycin MIC (µg/mL)</th>
<th>Teicoplanin MIC (µg/mL)</th>
<th>Specimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. epidermidis (VISE)</td>
<td>1</td>
<td>8 (Intermediate)</td>
<td>4 (Susceptible)</td>
<td>Blood</td>
</tr>
</tbody>
</table>

**Table 3. Details of Vancomycin Intermediate Staphylococcus epidermidis (VISE) Isolates**

<table>
<thead>
<tr>
<th>Isolate</th>
<th>P 10 µg</th>
<th>ERY 15 µg</th>
<th>CX 30 µg</th>
<th>CTX 30 µg</th>
<th>CIP 5 µg</th>
<th>COT 1.25/23.75 µg</th>
<th>GM 10 µg</th>
<th>VAN (MIC)</th>
<th>TEI (MIC)</th>
<th>LZ 30 µg</th>
<th>RIF 5 µg</th>
<th>RP 15 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISE</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>R</td>
<td>S</td>
<td>I</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
</tbody>
</table>

**Table 4. Antibiogram of the VISE Isolates**

S- Susceptible, I- Intermediate, R- Resistant.

**Abbreviation**

Phenotypic detection of Glycopeptide resistance among Methicillin Resistant Staphylococci by various methods showed one isolate to be Vancomycin Intermediate S.epidermidis (VISE) from blood sample. This isolate was susceptible to Gentamicin, Teicoplanin, Linezolid, Rifampicin, Quinupristin/Dalfopristin by reference CLSI methods.

**DISCUSSION**

Nowadays, CoNS has emerged as a pathogen causing serious nosocomial infections, particularly in immunocompromised patients and those suffering from chronic illnesses. It has been found that Methicillin resistance is more prevalent among CoNS that led to the increased use of glycopeptides as empirical therapy. In recent years, Glycopeptides Resistant CoNS (GRCoNS) have increasingly been reported. The emergence of resistance to Glycopeptides like Vancomycin and Teicoplanin in Staphylococci will have a significant impact on the treatment outcome. Hence, early detection of Glycopeptide resistance is of great clinical significance in combating resistance. In view of this above perspective, the current study was conducted to know the prevalence of Glycopeptide resistance in our geographical area by various phenotypic methods. A total of 104 Staphylococcus species were isolated from various clinical samples. The present study detected 28 (26.92%) MRCoNS. Rachana Solanki et al (2012) documented 59.2% MRCoNS. Surekha Y Asangi et al (2011) documented 67.7% MRCoNS. The sample wise distribution of MRCoNS was analysed, which showed 21 (20.19%) were from pus followed by blood (4.81%). The department wise isolation of MRCoNS showed 32.14% were from surgery and 25% from orthopaedic wards.

**Phenotypic Detection of Glycopeptide Resistance among Methicillin Resistant Staphylococci by Vancomycin Screen Agar**

The phenotypic detection of Glycopeptide resistance by vancomycin screen agar (BHIA-6V) showed out of 28 only one (3.6%) isolate grew on it. Dr. Dhanalakshmi TA, Umaphathy BL et al (2012) have stated that the Vancomycin screen agar test method with detection of VRSA in their study from Karnataka, India. Gandham Pavani (2012) has concluded in his study from Andhra Pradesh, India, that Vancomycin screen agar can be used as a method for Vancomycin resistant since it showed 100% specificity and 100% negative predictive value.

**Phenotypic Detection of Glycopeptide Resistance among MRCoNS by E-Test Method and Broth Microdilution**

Glycopeptide resistant detection of the 28 MRCoNS isolates by E-test method with vancomycin showed 27 (96.4%) of isolates to be Vancomycin Susceptible CoNS with MIC ≤ 4 mcg/mL. Only 1 (3.6%) isolate was found to be VISE (Vancomycin intermediate S. epidermidis) with MIC 8mcg/mL. No VRCoNS was detected. E-test method with Teicoplanin showed all the MRCoNS isolates to be 100% susceptible.

The glycopeptides resistant detection with vancomycin by CLSI reference broth microdilution method showed 27 (96.4%) of isolates to be Vancomycin Susceptible CoNS with MIC ≤ 4 mcg/mL. Only 1 (3.6%) isolate was found to be VISE.
with MIC 8 mcg/mL. No VRCoNS was detected. BMD method with Teicoplanin showed all the MRCoNS isolates to be 100% susceptible.

The present study showed the prevalence of VISE to be 1 (3.6%) among 28 MRCoNS strains. The MIC by E-test and BMD showed concordant results in this study.

**Various Studies showing the Prevalence of Glycopeptide Resistance among Coagulase Negative Staphylococci**

Evelina Taconelli et al. 2001[9] Italy documented 3.73% Glycopeptide resistant CoNS (among CoNS) by E-test method. Harekrishna Tiwari et al. 2006[10] Varanasi, India have reported 1.07% GRCoNS and 2.15% Glycopeptide intermediate CoNS (among CoNS) by Agar dilution method. GA Menzes and BN Harish et al. 2008 Pondicherry, India have documented 23.8% vancomycin intermediate CoNS (among MRCoNS) by E-test method.

Silvia Natoli et al. 2009[12] Italy documented 5.4% CoNS with reduced susceptibility to glycopeptides (among CoNS) by E-test in blood samples of patients from haematology wards. Rachna Solanki et al. 2011[13] Vadodara, India have shown 1.63% VRCoNS (among MRCoNS) by E-test method.

S Tevell et al. 2013[14] Sweden documented 11.5% Teicoplanin resistant CoNS (among S. epidermidis) by E-test method. Sunil B Bhamare et al. 2014[14] Pune, India have documented 1.8% VRCoNS (among MRCoNS) by Broth microdilution method. Xiao Xue Ma, En Hua Wang et al. (2011)[15] have documented the prevalence of CoNS strains non-susceptible to Teicoplanin increased from 4.5% - 6.7% between 2008 and 2009.

**The Present Study Detected 1 (3.6%) VISE Isolate (among MRCoNS) by E-test and Broth Microdilution Method**

The present study showed the prevalence of Vancomycin Intermediate CoNS to be 3.6%. This was concordant with the study conducted by Harekrishna Tiwari et al. 2006[10] who have documented 2.15% of Glycopeptide intermediate CoNS. In the present study, the VISE isolate was isolated from blood sample of a patient with infective endocarditis. This isolate was multidrug resistant but was susceptible to Gentamicin, Teicoplanin, Linezolid, Rifampicin, Quinupristin/ Dalteparistin by reference CLSI methods. Adina C Musta, Kathleen Riederer et al. (2009)[16] have compared MIC by E-test method and standard microdilution method and found the results to be concordant for the most isolates. FW Goldstein, A Coutrot et al. (1990)[17] have demonstrated that susceptibility of Coagulase negative staphylococci to Teicoplanin cannot be inferred from results of tests of vancomycin susceptibility and testing for Teicoplanin susceptibility should be routinely determined for patients treated with Teicoplanin.

**CONCLUSION**

Staphylococci is notorious for causing wide range of hospital and community acquired infection, because of the emergence of resistance to multiple antibiotics and limited therapeutic options. The prevalence of Vancomycin Intermediate Staphylococcus epidermidis (VISE) was 3.6%. Early detection of these strains is crucial to establish an appropriate antimicrobial therapy, thereby reducing the mortality and morbidity associated with these infections and also to prevent hospital acquired infections. On comparison of various phenotypic methods, E-test can be used to detect Glycopeptide resistance since it is simple and easy to use despite its cost when compared to broth microdilution which is labour intensive and needs special training. Formulating antibiotic policy and following them, judicial use of higher antibiotics, strict aseptic precautions are the measures that can be taken to combat the serious therapeutic challenge faced with emerging multi-drug resistant Staphylococcus species.

**REFERENCES**

[10] Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infectious Diseases 2006;6:156.


